Pharmacokinetic, pharmacodynamic and clinical evaluation of saxagliptin in type 2 diabetes

Expert Opinion on Drug Metabolism and Toxicology

Volumn 12, Issue 4, 2016, Pages 467-473

  Anderson, Rose ^a   Hayes, Jennifer ^a   Stephens, Jeffrey W ^a,b  

^a MORRISTON HOSPITAL   (United Kingdom)

^b SWANSEA UNIVERSITY   (United Kingdom)

Author keywords

DPP 4; glucagon like peptide 1; saxagliptin

Indexed keywords

GLUCOSE; SAXAGLIPTIN; ADAMANTANE; DIPEPTIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; INSULIN; SULFONYLUREA DERIVATIVE;

ARTICLE; CARDIOVASCULAR RISK; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREATITIS; PHARMACODYNAMICS; SIDE EFFECT; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; COMBINATION DRUG THERAPY; DIABETES MELLITUS, TYPE 2; DOSE RESPONSE; META ANALYSIS (TOPIC); METABOLISM; PHASE 3 CLINICAL TRIAL (TOPIC); POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; TREATMENT OUTCOME;

ADAMANTANE; BLOOD GLUCOSE; CLINICAL TRIALS, PHASE III AS TOPIC; DIABETES MELLITUS, TYPE 2; DIPEPTIDES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN; META-ANALYSIS AS TOPIC; POSTPRANDIAL PERIOD; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SULFONYLUREA COMPOUNDS; TREATMENT OUTCOME;

EID: 84961216425     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2016.1154044     Document Type: Article

References (47)

1. Jain R. Utility of saxagliptin in the treatment of type 2 diabetes: review of efficacy and safety. Adv Ther. 2015; 32: 1065-1084.
2. Dhillon S. Saxagliptin: A review in type 2 diabetes. Drugs. 2015; 75: 1783-1796.
3. Rosenstock J, Aguilar-Salinas C, Klein E, et al. Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes. Curr Med Res Opin. 2009; 25: 2401-11.
4. DeFronzo RA, Hissa MN, Garber AJ, et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care. 2009; 32: 1649-1655.
5. Pfutzner A, Paz-Pacheco E, Allen E, et al. Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Diabetes Obes Metab. 2011; 13: 567-576.
6. Scheen AJ. Saxagliptin plus metformin combination in patients with type 2 diabetes and renal impairment. Expert Opin Drug Metab Toxicol. 2012; 8: 383-394.
7. Hollander P, Li J, Allen E, et al. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. J Clin Endocrinol Metab. 2009; 94: 4810-4819.
8. Chacra AR, Tan GH, Ravichandran S, et al. Safety and efficacy of saxagliptin in combination with submaximal sulphonylurea versus up-Titrated sulphonylurea over 76 weeks. Diab Vasc Dis Res. 2011; 8: 150-159.
9. Barnett AH, Charbonnel B, Donovan M, et al. Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin. Curr Med Res Opin. 2012; 28: 513-523.
10. Rosenstock J, Hansen L, Zee P, et al. Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: A randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin. Diabetes Care. 2015; 38: 376-83.
11. Cole PSN, Serradell N, Bolos J, et al. Saxagliptin. Drugs Future. 2008; 33 (7): 577-586.
12. Augeri DJ, Robl JA, Betebenner DA, et al. Discovery and preclinical profile of Saxagliptin (BMS-477118): A highly potent, long-Acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem. 2005; 48: 5025-5037.
13. Boulton DW, Li L, Frevert EU, et al. Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin. Clin Pharmacokinet. 2011; 50: 253-65.
14. Nowicki M, Rychlik I, Haller H, et al. Long-Term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: A randomised controlled 52-week efficacy and safety study. Int J Clin Pract. 2011; 65: 1230-1239.
15. Barnett AH, Charbonnel B, Li J, et al. Saxagliptin add-on therapy to insulin with or without metformin for type 2 diabetes mellitus: 52-week safety and efficacy. Clin Drug Investig. 2013; 33: 707-717.
16. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013; 369: 1317-1326.
17. Dhillon S, Weber J. Saxagliptin. Drugs. 2009; 69: 2103-2114.
18. Golightly LK, Drayna CC, McDermott MT. Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors. Clin Pharmacokinet. 2012; 51: 501-514.
19. Scheen AJ. Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes. Expert Opin Drug Saf. 2015; 14: 505-524.
20. Fura A, Khanna A, Vyas V, et al. Pharmacokinetics of the dipeptidyl peptidase 4 inhibitor saxagliptin in rats, dogs, and monkeys and clinical projections. Drug Metab Dispos. 2009; 37: 1164-1171.
21. Patel CG, Kornhauser D, Vachharajani N, et al. Saxagliptin, a potent, selective inhibitor of DPP-4, does not alter the pharmacokinetics of three oral antidiabetic drugs (metformin, glyburide or pioglitazone) in healthy subjects. Diabetes Obes Metab. 2011; 13: 604-614.
22. Tahrani AA, Piya MK, Barnett AH. Saxagliptin: A new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus. Adv Ther. 2009; 26: 249-262.
23. Ali S, Fonseca V. Saxagliptin overview: special focus on safety and adverse effects. Expert Opin Drug Saf. 2013; 12: 103-109.
24. Scheen AJ. Pharmacokinetics and clinical use of incretin-based therapies in patients with chronic kidney disease and type 2 diabetes. Clin Pharmacokinet. 2015; 54: 1-21.
25. Ramirez G, Morrison AD, Bittle PA. Clinical practice considerations and review of the literature for the Use of DPP-4 inhibitors in patients with type 2 diabetes and chronic kidney disease. Endocr Pract. 2013; 19: 1025-1034.
26. Udell JA, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial. Diabetes Care. 2015; 38: 696-705.
27. Nowicki M, Rychlik I, Haller H, et al. Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment. Diabetes Obes Metab. 2011; 13: 523-532.
28. Scheen AJ. Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions. Clin Pharmacokinet. 2010; 49: 573-588.
29. Mudaliar S. Choice of early treatment regimen and impact on beta-cell preservation in type 2 diabetes. Int J Clin Pract. 2013; 67: 876-887.
30. Scheen AJ, Charpentier G, Ostgren CJ, et al. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus. Diabetes Metab Res Rev. 2010; 26: 540-549.
31. Moses RG, Kalra S, Brook D, et al. A randomized controlled trial of the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea. Diabetes Obes Metab. 2014; 16: 443-450.
32. Scheen AJ. Metformin + saxagliptin for type 2 diabetes. Expert Opin Pharmaco. 2012; 13: 139-146.
33. Goke B, Gallwitz B, Eriksson J, et al. Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: A 52-week randomised controlled trial. Int J Clin Pract. 2010; 64: 1619-1631.
34. Williams DM, Stephens JW. Combination therapy with saxagliptin and dapagliflozin for the treatment of type 2 diabetes. Expert Opin Pharmaco. 2015; 16: 2373-2379.
35. Yagi S, Aihara K, Akaike M, et al. Predictive factors for efficacy of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus. Diabetes Metab J. 2015; 39: 342-347.
36. Esposito K, Chiodini P, Maiorino MI, et al. A nomogram to estimate the HbA1c response to different DPP-4 inhibitors in type 2 diabetes: A systematic review and meta-Analysis of 98 trials with 24 163 patients. BMJ Open. 2015; 5: e005892.
37. Gross JL, Rogers J, Polhamus D, et al. A novel model-based meta-Analysis to indirectly estimate the comparative efficacy of two medications: An example using DPP-4 inhibitors, sitagliptin and linagliptin, in treatment of type 2 diabetes mellitus. BMJ Open. 2013; 3: e001844-e001844.
38. Schernthaner G, Duran-Garcia S, Hanefeld M, et al. Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: A randomized, controlled study (GENERATION). Diabetes Obes Metab. 2015; 17: 630-638.
39. Davidson JA. Tolerability of saxagliptin in patients with inadequately controlled type 2 diabetes: results from 6 phase III studies. Journal Managed Care Pharmacy: JMCP. 2014; 20: 120-129.
40. Frederich R, Alexander JH, Fiedorek FT, et al. A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. Postgrad Med. 2010; 122: 16-27.
41. Scirica BM, Braunwald E, Raz I, et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation. 2014; 130: 1579-88.
42. Iqbal N, Parker A, Frederich R, et al. Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials. Cardiovasc Diabetol. 2014; 13: 33.
43. Iqbal N, Allen E, Öhman P. Long-Term safety and tolerability of saxagliptin add-on therapy in older patients (aged ≥ 65 years) with type 2 diabetes. Clin Interv Aging. 2014; 9: 1479-1487.
44. Giorda CB, Sacerdote C, Nada E, et al. Incretin-based therapies and acute pancreatitis risk: A systematic review and meta-Analysis of observational studies. Endocrine. 2015; 48: 461-471.
45. Raz I, Bhatt DL, Hirshberg B, et al. Incidence of pancreatitis and pancreatic cancer in a randomized controlled multicenter trial (SAVOR-TIMI 53) of the dipeptidyl peptidase-4 inhibitor saxagliptin. Diabetes Care. 2014; 37: 2435-2441.
46. Leiter LA, Teoh H, Mosenzon O, et al. Frequency of cancer events with saxagliptin in the SAVOR-TIMI 53 trial. Diabetes Obes Metab. 2016; 18: 186-190.
47. Bryzinski B, Allen E, Cook W, et al. Saxagliptin efficacy and safety in patients with type 2 diabetes receiving concomitant statin therapy. J Diabetes Complications. 2014; 28: 887-893.